Allergan, Inc. Product Pipeline Analysis

Publication Date	May 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	55
ISBN Number	not applicable
Product Code	GMD04702

Price

£505.00
approximately: $750 | €594

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a Allergan, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reason to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
3 Allergan, Inc. Pipeline Products
- 3.1 Allergan, Inc. Product Pipeline Analysis
  - 3.1.1 Allergan, Inc. Pipeline Products By Equipment Type
  - 3.1.2 Allergan, Inc. Pipeline Products By Development Stage
  - 3.1.3 Allergan, Inc. Pipeline Products By Therapy Area
  - 3.1.4 Allergan, Inc. Pipeline Products By Clinical Trials
  - 3.1.5 Allergan, Inc. Pipeline Products By News Summary
- 3.2 Silicone Breast Implant -Cohesive Silicone Gel Matrix (Style 410)
  - 3.2.1 Product Description
  - 3.2.2 Product Status
- 3.3 VOLUMA
  - 3.3.1 Product Description
  - 3.3.2 Product Status
- 3.4 EASYBAND
  - 3.4.1 Product Description
  - 3.4.2 Product Status
  - 3.4.3 Clinical Trials
- 3.5 BioEnterics Intragastric Balloon
  - 3.5.1 Product Description
  - 3.5.2 Product Status
  - 3.5.3 Product Milestone
  - 3.5.4 Product Patent Details
  - 3.5.5 Product Patent Details
- 3.6 LAP-BAND
  - 3.6.1 Product Description
  - 3.6.2 Product Status
  - 3.6.3 Clinical Trials
  - 3.6.4 Product Patent Details
  - 3.6.5 Product Patent Details
4 Business Description
- 4.1 Business Overview
- 4.2 Major Products and Services
  - 4.2.1 Overview
5 History
6 Competitors
7 Key Employees
8 Key Employee Biographies
9 Company Statement
10 Locations And Subsidiaries
- 10.1 Head Office
- 10.2 Other Locations & Subsidiaries
11 Financial Deals Landscape
- 11.1 Acquisition
  - 11.1.1 Allergan Acquires Esprit Pharma
  - 11.1.2 Allergan Acquires Endoart
- 11.2 Debt Offerings
  - 11.2.1 Allergan Completes Private Placement Of Convertible Senior Notes
  - 11.2.2 Allergan Completes Private Placement Of Senior Notes
- 11.3 Partnership
  - 11.3.1 Covidien Signs An Agreement With Allergan
12 Recent Developments
- 12.1 Financial Announcements
  - 12.1.1 May 07, 2008: Allergan Declares Quarterly Dividend
  - 12.1.2 May 07, 2008: Allergan Declares Q1 2008 Results
  - 12.1.3 Jan 30, 2008: Allergan Declares Quarterly Dividend
  - 12.1.4 Jan 30, 2008: Allergan Declares Q4 2007 Results
  - 12.1.5 Nov 06, 2007: Allergan Declares Quarterly Dividend
  - 12.1.6 Nov 06, 2007: Allergan Declares Q3 2007 Results
  - 12.1.7 Aug 01, 2007: Allergan Reports Q2 2007 Results
  - 12.1.8 Aug 01, 2007: Allergan Declares Quarterly Dividend
  - 12.1.9 May 02, 2007: Allergan Reports Q1 2007 Results
  - 12.1.10 May 02, 2007: Allergan Declares Quarterly Dividend
  - 12.1.11 Jan 31, 2007: Allergan Reports Q4 2006 Results
  - 12.1.12 Jan 31, 2007: Allergan Declares Quarterly Dividend
- 12.2 Other Significant Developments
  - 12.2.1 Dec 06, 2007: Allergan Appoints Board Member
13 Appendix
- 13.1 Methodology
  - 13.1.1 Coverage
  - 13.1.2 Secondary Research
  - 13.1.3 Primary Research
  - 13.1.4 Expert Panel Validation
- 13.2 Contact Us
- 13.3 About Global Markets Direct
- 13.4 Disclaimer
List of Tables
- Table 1: Allergan, Inc.,Key Facts
- Table 2: Allergan, Inc. Pipeline Products by Equipment Type
- Table 3: Allergan, Inc. Pipeline Products By Development Stage
- Table 4: Allergan, Inc. Pipeline Products By Therapy Area
- Table 5: Allergan, Inc. Pipeline Products By Clinical Trials
- Table 6: Allergan, Inc. Pipeline Products By News Summaries
- Table 8: Allergan, Inc., Key Employees,
- Table 9: Allergan, Inc., Subsidiaries
List of Figures
- Figure 1: Global Markets Direct Methodology